뇌 질환 연구용 EGFRvIII 과발현 세포주
본문
뇌 질환 연구용 EGFRvIII 과발현 세포주
U87MG vIII 4.12
The U87MG vIII 4.12 clone cell line is a permanent line established from cell line derived from malignant glioma, classified as glioblastoma. U87MG vIII (4.12) cell line stably expresses high level of EGF mutant receptor vIII and G418-resistant genes introduced by plasmid stable transfection.
T96/EGFRvIII
The T96 cell line is established from glioblastoma multiforme. The T96/EGFRvIII with additional point mutation C311Y cell line stably expresses mutated EGFRvIII and neomicin-resistant genes. Both mutated EGFRvIII and neomicin-resistant genes are under CMV promoter control, allowing high levels of protein expression.
DKMG/EGFR vIII
Application of the DKMG/EGFRvIII cell line opens new perspectives in EGFRvIII research. EGFRvIII expression was reinduced in cells, which expressed EGFRvIII in vivo, but due to unknown reasons did not in vitro. DKMG cells show mutation at DNA level, which is responsible for the expression of EGFRvIII mRNA and protein, however, in most of these cells the expression of mutatant EGFR gene copies is silenced (these cells show the amplification of this gene). The performed biotechnological modification results in the EGFRvIII expression in all cells of the DKMG cell line.
Ordering informations
|
▣ 관련 페이지 ; Celther Polska
댓글목록
등록된 댓글이 없습니다.